{
  "id": 12115045,
  "title": "Mizuho initiates Regenxbio stock coverage with outperform rating",
  "url": "https://urgent.news/2026/10/05/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T09:10:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating-93CH-4931341"
  },
  "original_language": "en",
  "account": null,
  "summary": "Mizuho initiated coverage on Regenxbio Inc. (NASDAQ: RGNX) with an outperform rating and set a price target of $22.00, representing nearly 196% upside from the current stock price of $7.43, which has declined 48% year-to-date. The firm highlighted the company’s development of gene therapy-based candidates for diseases with high unmet need as the basis for its rating. Mizuho’s model focuses on two lead assets in the company’s pipeline: RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314, also known as sura-vec, for wet age-related macular degeneration and diabetic retinopathy.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}